View:
Download DOC
Download PDF
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Morgan Bradley Paul
(Last) (First) (Middle)
280 EAST GRAND AVENUE
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP Drug Discovery & Early Dev
3. Date of Earliest Transaction (Month/Day/Year)
03/15/2006
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy) $6 03/05/2013 A 21,204 04/05/2013(1) 03/05/2023 Common Stock 21,204 $0.0 21,204 D
Incentive Stock Option (right to buy) $6.3 03/05/2012 A 13,920 04/05/2012(2) 03/05/2022 Common Stock 13,920 $0.0 13,920 D
Incentive Stock Option (right to buy) $6.67 02/23/2016 A 18,817 03/23/2016(3) 02/23/2026 Common Stock 18,817 $0.0 18,817 D
Incentive Stock Option (right to buy) $7.96 02/26/2015 A 11,044 03/26/2015(4) 02/26/2025 Common Stock 11,044 $0.0 11,044 D
Incentive Stock Option (right to buy) $9.42 02/28/2011 A 11,883 03/28/2011(5) 02/28/2021 Common Stock 11,883 $0.0 11,883 D
Incentive Stock Option (right to buy) $9.65 02/24/2014 A 18,448 03/24/2014(6) 02/24/2024 Common Stock 18,448 $0.0 18,448 D
Incentive Stock Option (right to buy) $11.1 02/26/2009 A 2,638 03/26/2009(7) 02/26/2019 Common Stock 2,638 $0.0 2,638 D
Incentive Stock Option (right to buy) $11.1 02/26/2009 A 2,639 03/26/2009(7) 02/26/2019 Common Stock 2,639 $0.0 5,277 D
Incentive Stock Option (right to buy) $18.48 02/24/2010 A 3,333 03/24/2010(8) 02/24/2020 Common Stock 3,333 $0.0 3,333 D
Incentive Stock Option (right to buy) $18.48 02/24/2010 A 4,278 03/24/2010(9) 02/24/2020 Common Stock 4,278 $0.0 7,611 D
Incentive Stock Option (right to buy) $20.22 02/29/2008 A 2,101 03/29/2008(10) 02/28/2018 Common Stock 2,101 $0.0 2,101 D
Incentive Stock Option (right to buy) $40.86 03/14/2007 A 3,106 04/14/2007(11) 03/14/2017 Common Stock 3,106 $0.0 3,106 D
Incentive Stock Option (right to buy) $42.24 03/15/2006 A 5,000 04/01/2006(12) 03/15/2016 Common Stock 5,000 $0.0 5,000 D
Non-Qualified Stock Option (right to buy) $6 03/05/2013 A 3,795 04/05/2013(1) 03/05/2023 Common Stock 3,795 $0.0 3,795 D
Non-Qualified Stock Option (right to buy) $6.3 03/05/2012 A 1,079 04/05/2012(2) 03/05/2022 Common Stock 1,079 $0.0 1,079 D
Non-Qualified Stock Option (right to buy) $6.67 02/23/2016 A 31,183 03/23/2016(3) 02/23/2026 Common Stock 31,183 $0.0 31,183 D
Non-Qualified Stock Option (right to buy) $7.96 02/26/2015 A 18,956 03/26/2015(4) 02/26/2025 Common Stock 18,956 $0.0 18,956 D
Non-Qualified Stock Option (right to buy) $9.42 02/28/2011 A 617 03/28/2011(5) 02/28/2021 Common Stock 617 $0.0 617 D
Non-Qualified Stock Option (right to buy) $9.65 02/24/2014 A 11,552 03/24/2014(6) 02/24/2024 Common Stock 11,552 $0.0 11,552 D
Non-Qualified Stock Option (right to buy) $11.1 02/26/2009 A 695 03/26/2009(7) 02/26/2019 Common Stock 695 $0.0 695 D
Non-Qualified Stock Option (right to buy) $11.1 02/26/2009 A 694 03/26/2009(7) 02/26/2019 Common Stock 694 $0.0 1,389 D
Non-Qualified Stock Option (right to buy) $18.48 02/24/2010 A 721 03/24/2010(9) 02/24/2020 Common Stock 721 $0.0 721 D
Non-Qualified Stock Option (right to buy) $20.22 02/29/2008 A 1,033 03/29/2008(10) 02/28/2018 Common Stock 1,033 $0.0 1,033 D
Non-Qualified Stock Option (right to buy) $40.86 03/14/2007 A 193 04/14/2007(11) 03/14/2017 Common Stock 193 $0.0 193 D
Explanation of Responses:
1. When the ISO and NQ dated 03/05/2013 are combined for a total grant of 24,999 shares, the option shall vest and become exercisable as to 520 shares on 04/05/2013 and the balance of 24,479 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/05/2017.
2. When the ISO and NQ dated 03/05/2012 are combined for a total grant of 14,999 shares, the option shall vest and become exercisable as to 312 shares on 04/05/2012 and the balance of 14,687 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/05/2016.
3. When the ISO and NQ dated 02/23/2016 are combined for a total grant of 50,000 shares, the option shall vest and become exercisable as to 50,000 shares divided into equal monthly installments such that the option shall be 100% vested on 02/23/2020.
4. When the ISO and NQ dated 02/26/2015 are combined for a total grant of 30,000 shares, the option shall vest and become exercisable as to 625 shares on 03/26/2015 and the balance of 29,375 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/26/2019.
5. When the ISO and NQ dated 02/28/2011 are combined for a total grant of 12,500 shares, the option shall vest and become exercisable as to 260 shares on 03/31/2011 and the balance of 12,240 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/28/2015.
6. When the ISO and NQ dated 02/24/2014 are combined for a total grant of 30,000 shares, the option shall vest and become exercisable as to 625 shares on 03/24/2014 and the balance of 29,375 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/2018.
7. When the ISO and NQ's dated 02/26/2009 are combined for a total grant of 6,666 shares, the option shall vest and become exercisable as to 138 shares on 03/26/09 and the balance of 6,528 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/26/13.
8. This option shall vest and become exercisable as to 69 shares on 03/24/10 and the balance of 3,264 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/14.
9. When the ISO and NQ dated 02/24/2010 are combined for a total grant of 4,999 shares, the option shall vest and become exercisable as to 104 shares on 03/24/2010 and the balance of 4,895 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/24/2014.
10. When the ISO and NQ dated 02/29/2008 are combined for a total grant of 3,134 shares, the option shall vest and become exercisable as to 65 shares on 03/29/08 and the balance of 3,069 divided into equal monthly installments thereafter such that the option shall be 100% vested on 02/29/12.
11. When the ISO and NQ dated 03/14/2007 are combined for a total grant of 3,299 shares, the option shall vest and become exercisable as to 68 shares on 04/01/07 and the balance of 3,231 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/11.
12. This option shall vest and become exercisable as to 104 shares on 04/01/06 and the balance of 4,896 divided into equal monthly installments thereafter such that the option shall be 100% vested on 03/01/10.
Bradley Morgan 02/25/2016
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

      The undersigned, as a Section 16 reporting person of
Cytokinetics, Incorporated (the Company), hereby constitutes and
appoints Sharon A. Barbari and Robert I. Blum, and each of them, the
undersigned's true and lawful attorney-in-fact to

1.	complete and execute Forms 3, 4 and 5 and other forms and
all amendments thereto as such attorney-in-fact shall in
his or her discretion determine to be required or
advisable pursuant to Section 16 of the Securities
Exchange Act of 1934 (as amended) and the rules and
regulations promulgated thereunder, or any successor laws
and regulations, as a consequence of the undersigneds
ownership, acquisition or disposition of securities of
the Company; and

2.	do all acts necessary in order to file such forms with
the Securities and Exchange Commission, any securities
exchange or national association, the Company and such
other person or agency as the attorney-in-fact shall deem
appropriate.

      The undersigned hereby ratifies and confirms all that said
attorneys-in-fact and agents shall do or cause to be done by virtue
hereof.  The undersigned acknowledges that the foregoing attorneys-
in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of
the undersigneds responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934 (as amended).

      This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4, and
5 with respect to the undersigneds holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the Company and the
foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 16th day of November, 2015.


Signature:	 /s/Bradley Morgan

Print Name:	Bradley Morgan